Males w/ sarcoidosis may be more likely to have cardiac involvement. Patients treated with s/bDMARDs had a high response rate as reflected by clinical and imaging improvement. Abs 1846 @RheumNow #ACR22 https://t.co/ibbf4Dckun https://t.co/ZvGxPNFjwm

• Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease …

In bio-naïve PsA pts on GUS, earlier improvements in self-reported health-related measures were sustained through 2 years. Abs 1850 #ACR22 @RheumNow https://t.co/6yhPesE3LZ https://t.co/nVCSgPgcqW

• Guselkumab Provides Sustained Improvements in Health-Related Quality of Life in…

#ACR22 Abstr#L07 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without). No major safety. Phase 3 in US is in progress. Would be historic! @RheumNow #ACRBest https://t.co/8wL2tkA8ym

Jonassen et al. AP1189, an oral melanocortin agonist in combination with MTX in early RA. Evidence of efficacy, no safety concerns. Looks promising! @RheumNow #ACR22 Abstr#1985 https://t.co/aK7BPwr5Ku https://t.co/9553KT2Pao

• The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-co…

van Ouwerkerk et al. Glucocorticoid bridging in new RA associated higher risk of starting bDMARD (aHR 1.68) but not glucocorticoids (aHR 1) later in disease. Why? Maybe it shows what can be achieved? @RheumNow #ACR22 Abstr#1994 https://t.co/5GsXGMOZAm https://t.co/122CuSAqVw

• Is Glucocorticoid Bridging Associated with Later Glucocorticoid and Biological …

Damart et al. Treatment strategies in CPP arthritis. Colchicine(1st line=73/86), MTX (second line=22/36), anakinra (n=27) and TCZ (n=25) most used. Drug survival MTX vs colchicine HR 0.64, TCZ vs anakinra HR 0.55 @RheumNow #ACR22 Abstr#1795 https://t.co/4PtxQNmTqV https://t.co/BKM4Ff9Gkk

• Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyro…

#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p

• Aromatase Inhibitor Induced Musculoskeletal Inflammation Is Observed Independen…

Are we asking women with IPAF about family planning? Abstract #0944 #ACR22 @RheumNow 🫁 31 women 🤰83% had RF for adverse pregnancy outcomes 👼1/3 women had family plan. or birth control talks with pulm. docs ✋>50% women who saw a rheumatologist discussed these topics

Rheum/ILD combined clinics may help dx ILD assoc'd CTD that is underdiagnosed currently. Pic below is very informative! Abs 1874 #ACR22 @RheumNow https://t.co/rr0QEfqicv https://t.co/V6eTyz1BuV

• Autoantibodies Are Common in Patients with Idiopathic Interstitial Lung Disease…

Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT https://t.co/CqK0dL7DQK

• Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatmen…

#abst2109 #ACR22 @RheumNow GO-VIBRANT bio-naïve pts w/active PsA Rx w/IV GLM tend respond slower in all domains if ⬆️ age, HAQ-DI score, and spinal pain; smoking gives w/lower odds of HAQ-DI ≤0.5 at W52. minimal SJC& ⬇️enthesitis achieved significantly faster than TJC, HAQ-DI https://t.co/qqmjEAq3Cd

#ACR22 Abstr#L08 Is Evusheld effective in the first 6 mths of therapy in #COVID Omicron era? A cohort study of 157 RMD patients who were fully vaccinated reported 24 (15%) breakthrough infection; only 2 (1%) required hospitalisation. COVID occurred ~3mths post-therapy @RheumNow https://t.co/VJogB2otbn

Possible new biomarker in early RA? RA patients with high level of measurable fibrogenesis (PRO-C3 serum levels) less likely to respond to TCZ, as compared to patients with low level of fibrogenesis. Abs 1986 #ACR22 @RheumNow https://t.co/xnyoV2xbWq https://t.co/Vka8UZsrar

• Early-stage Rheumatoid Arthritis Patients with High Levels of Type III Collagen…

@RheumNow #ACR22 https://t.co/dO7xDTApqP

• https://twitter.com/lupusreference/status/1592180328491368449

Immunosuppressants (eg. MTX, RTX, MMF) can reduce immunogenicity to vaccines. VACIMRA study showing no difference in disease activity (beyond 1 month) and damage when MTX initiation was delayed by 1 month for the PCV13 pneumococcal vaccine. @RheumNow ABST1960 #ACR22 https://t.co/SKQ2qx3lJG